Edition:
United Kingdom

Akers Biosciences Inc (AKER.OQ)

AKER.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
16 Sep 2019
Change (% chg)

$0.02 (+4.00%)
Prev Close
$0.50
Open
$0.52
Day's High
$0.52
Day's Low
$0.51
Volume
17,451
Avg. Vol
30,159
52-wk High
$3.92
52-wk Low
$0.40

Latest Key Developments (Source: Significant Developments)

Akers Biosciences Reports Q1 Operating Loss Of $0.9 Mln
Monday, 20 May 2019 

May 20 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES REPORTS Q1 2019 EARNINGS.AKERS BIOSCIENCES INC - BOARD IS CONSIDERING A RANGE OF POTENTIAL STRATEGIC ALTERNATIVES.AKERS BIOSCIENCES INC - AT MARCH 31, 2019, AKERS BIO HAD CASH, RESTRICTED CASH AND MARKETABLE SECURITIES OF $5.23 MILLION..AKERS BIOSCIENCES INC - RECURRING EXPENSES ARE ANTICIPATED TO BE MATERIALLY LOWER THROUGHOUT REMAINDER OF 2019 THAN SAME PERIOD IN 2018.AKERS BIOSCIENCES INC - QTRLY OPERATING LOSS WAS $0.9 MILLION.  Full Article

Akers Biosciences - Anticipated That Trading In Common Stock On Aim Will Cease, Delisting Will Take Effect, From 7.00 A.M. (Gmt) On March 29
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES - ANTICIPATED THAT TRADING IN COMMON STOCK ON AIM WILL CEASE, DELISTING WILL TAKE EFFECT, FROM 7.00 A.M. (GMT) ON MARCH 29.  Full Article

Akers Biosciences announces intention to explore strategic alternatives to maximize shareholder value
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES ANNOUNCES INTENTION TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE.AKERS BIOSCIENCES INC - PROCESS WILL CONSIDER A RANGE OF POTENTIAL STRATEGIC ALTERNATIVES INCLUDING BUSINESS COMBINATIONS.AKERS BIOSCIENCES INC - EFFECTING A REVERSE STOCK SPLIT OF ITS ISSUED AND OUTSTANDING COMMON STOCK.AKERS BIOSCIENCES - DOES NOT PLAN TO DISCLOSE OR COMMENT ON DEVELOPMENTS REGARDING STRATEGIC REVIEW PROCESS UNTIL IT IS COMPLETE.AKERS BIOSCIENCES INC - REVERSE STOCK SPLIT STOCK OF 1 SHARE OF COMMON STOCK FOR EVERY 8 SHARES OF COMMON STOCK ON NOV 8, 2018.  Full Article

Akers Biosciences Appoints Howard R Yeaton as Chief Executive Officer
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Akers Biosciences Inc ::ANNOUNCES A LEADERSHIP CHANGE, STRATEGIC UPDATE, LEGAL SETTLEMENT AND AN AIM UPDATE.SAYS HOWARD R. YEATON HAS BEEN APPOINTED TO POSITION OF CHIEF EXECUTIVE OFFICER EFFECTIVE IMMEDIATELY.SAYS JOHN GORMALLY HAS RESIGNED BOTH AS CHIEF EXECUTIVE OFFICER AND AS A MEMBER OF BOARD OF DIRECTORS OF COMPANY EFFECTIVE IMMEDIATELY.  Full Article

Akers Biosciences Announces Lifting Of Temporary Suspension Of Trading On The London Stock Exchange
Thursday, 26 Jul 2018 

July 26 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES ANNOUNCES LIFTING OF TEMPORARY SUSPENSION OF TRADING ON THE LONDON STOCK EXCHANGE.AKERS BIOSCIENCES - SUSPENSION OF TRADING IN CO'S SHARES ON LONDON STOCK EXCHANGE'S AIM MARKET LIFTED WITH EFFECT FROM 26 JULY AT 7.30 A.M. UK TIME.  Full Article

Akers Biosciences Withdraws FDA 510(K) Submission For PIFA
Tuesday, 29 May 2018 

May 29 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES WITHDRAWS FDA 510(K) SUBMISSION FOR PIFA CHLAMYDIA RAPID ASSAY PENDING FURTHER EVALUATION.AKERS BIOSCIENCES- DECIDED TO WITHDRAW INITIAL 510(K) APPLICATION FOR PIFA CHLAMYDIA TO RE-EVALUATE OPTIONS DUE TO THE PRODUCT DEVELOPMENT OPPORTUNITY.  Full Article

Akers Biosciences Files Non Timely 10-Q - SEC Filing
Wednesday, 16 May 2018 

May 16 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING.  Full Article

Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY.AKERS BIOSCIENCES INC - RAYMOND AKERS CONTINUES AS A MEMBER OF BOARD - SEC FILING.AKERS BIOSCIENCES INC - APPOINTED RICHARD CARLYLE TARBOX III AS INTERIM NON-EXECUTIVE CHAIRMAN.  Full Article

Akers Biosciences Signs Distribution Agreement With Diagnostica Stago
Monday, 26 Mar 2018 

March 26 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO.AKERS BIOSCIENCES - ENTERED 3-YEAR NATIONAL DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO INC.AKERS BIOSCIENCES - AGREEMENT FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US.  Full Article

Bigger Capital Fund Reports An 8 Pct Passive Stake In Akers Biosciences
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Biosciences Inc ::BIGGER CAPITAL FUND LP REPORTS AN 8 PCT PASSIVE STAKE IN AKERS AS OF DEC 21, 2017 - SEC FILING.  Full Article